Szklenarik György, Kiraly Peter, Szegvari Gabor, Dora David, Lohinai Zoltan
Translational Medicine Institute, Semmelweis University, Budapest, Hungary.
Department of Anatomy, Histology and Embryology, Semmelweis University, Budapest, Hungary.
Front Med (Lausanne). 2024 Nov 29;11:1488377. doi: 10.3389/fmed.2024.1488377. eCollection 2024.
Colonization of the human gut and tumor tissue by non-pathogenic fungi has emerged as a potential risk factor associated with cancer epidemics. Therefore, we aimed to conduct a systematic review to assess the role of fungal colonization in gastrointestinal (GI) tumors in increasing diagnostic efficiency.
A PubMed citation search was conducted for publications up to and including March 2023, followed by full-text screening. Results were reported according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. According to the Patient, Intervention, Comparison, Outcome (PICO) framework, patients diagnosed with early-and advanced-stage GI cancers, GI adenoma patients, and healthy subjects were included with metagenomic (MG) or internal transcribed spacer (ITS) sequencing on tumor tissue, adjacent normal tissue, stool, and blood samples.
Fourteen studies were eligible based on the inclusion criteria and methodological quality. Studies were conducted in stool ( = 8) or tissue ( = 7) as the most common specimens to be used for molecular analysis. In the collected data, ITS was used in = 10 cases and metagenomic analyses in = 3 cases. Observing the interindividual variability, we found that the Ascomycota/Basidiomycota (A/B) ratio from healthy to cancer state decreased in = 2, increased in = 1 cases, and did not change significantly in = 2 studies. An increase in the relative abundance of Malassezia was identified in = 4, of Candida in = 5, of Saccharomyces in = 2, and of Aspergillus in = 2 cases. Intraindividual differences in the A/B ratio were identified in cancer and adjacent tissue ( = 4) and cancer vs. stool ( = 1) studies. Intraindividual variability of the A/B ratio showed an increase in = 2 and no change in = 3 studies for cancer tissue.
In conclusion, the advent of highly sensitive sequencing methods may aid in the identification and the differentiation of cancerous from healthy human fungal colonizations with potential future diagnostic applications. Further studies are needed to establish reliable biomarkers for GI cancer screening.
非致病性真菌在人体肠道和肿瘤组织中的定殖已成为与癌症流行相关的一个潜在风险因素。因此,我们旨在进行一项系统评价,以评估真菌定殖在胃肠道(GI)肿瘤中对提高诊断效率的作用。
对截至2023年3月(含)的出版物进行PubMed文献检索,随后进行全文筛选。结果根据系统评价和Meta分析的首选报告项目(PRISMA)2020指南进行报告。根据患者、干预措施、对照、结局(PICO)框架,纳入诊断为早期和晚期GI癌症的患者、GI腺瘤患者以及健康受试者,对肿瘤组织、相邻正常组织、粪便和血液样本进行宏基因组(MG)或内转录间隔区(ITS)测序。
根据纳入标准和方法学质量,有14项研究符合条件。研究中最常用作分子分析的标本是粪便(n = 8)或组织(n = 7)。在收集的数据中,10例使用了ITS,3例进行了宏基因组分析。观察个体间差异,我们发现从健康状态到癌症状态,子囊菌门/担子菌门(A/B)比值在2项研究中降低,1项研究中升高,2项研究中无显著变化。在4项研究中发现马拉色菌相对丰度增加,5项研究中念珠菌增加,2项研究中酿酒酵母增加,2项研究中曲霉菌增加。在癌症与相邻组织(n = 4)以及癌症与粪便(n = 1)的研究中发现了A/B比值的个体内差异。对于癌症组织,A/B比值的个体内变异性在2项研究中增加,3项研究中无变化。
总之,高灵敏度测序方法的出现可能有助于识别和区分人类癌症性真菌定殖与健康真菌定殖,具有潜在的未来诊断应用价值。需要进一步研究以建立用于GI癌症筛查的可靠生物标志物。